BRAIN
High-Grade
NCCTG N0776 Consent
HIPAA
Protocol
Phase II Trial of Avastin®
in Combination with Sorafenib in Recurrent
GlioblastomaMultiforme
NCCTG N0779 Consent 1A
Consent 1B
HIPAA
Protocol
(closed 1/29/2010)
Phase II Study of Vorinostat (SAHA) in
combination with Bortezomib (PS-341) in Patients
with Recurrent Glioblastoma Multiforme
RTOG R0825 Consent
HIPAA
Protocol
Phase III Double-Blind Placebo-Controlled Trial
of Conventional Concurrent Chemoradiation and
Adjuvant Temozolomide plus Bevacizumab versus
Conventional Concurrent Chemoradiation and
Adjuvant Temozolomide in Patients with
Newly-Diagnosed Glioblastoma
Low-Grade
NCCTG N0272A(phase 1)
Consent
HIPAA
Protocol
(temporary closure Arm C-EIAC's patients) NCCTG N0272B(phase 2)
Consent
A Phase I/II Trial of Imatinib
Mesylate (Gleevec) in Treatment of Recurrent Oligodendroglioma and Mixed
Oligoastrocytoma
CTSU E3F05 Consent
HIPAA
Protocol
Phase III Study of Radiation Therapy with or
without Temozolomide for Symptomatic or
Progressive Low-Grade Gliomas
RTOG R0539 Consent
HIPAA
Protocol
Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for
Intermediate- and High-Risk
Brain Mets
NCCTG N0574
Consent
HIPAA
Protocol
Phase III
Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to
Radiosurgery in Patients with One to Three Cerebral Metastases
BREAST
Breast - Other
NSABP BP-59
Consent
HIPAA
Fast Facts
Protocol
Bone Marrow Analysis in
Early-Stage Breast Cancer
Breast DCIS
NSABP B43 Consent
Consent(pre-entry)
HIPAA
HIPAA(Pre-entry)
Protocol
Fast Facts
Treatment Calendar
A Phase III Clinical
Trial Comparing Trastuzumab Given Concurrently
with Radiation Therapy and Radiation Therapy
Alone for Women with HER2-Positive Ductal
Carcinoma In Situ Resected by Lumpectomy
Breast - Node
Negative
CTSU PACCT-1 TAILORx
Consent HIPAA
Fast Facts
Protocol
Patient Information
Treatment Calendar
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial
Assigning Individualized Options for Treatment: The TAILORx Trial
Breast -
Node Positive or Negative
SWOG S0221
Consent HIPAA
Protocol Fast
Facts
Antioxidant Use
Treatment
Calendar Arm 1
TC-Arm 2
TC-Arm 3
TC-Arm 4
Phase III Trial of Continuous Schedule AC + G
vs. Q-2
Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks
as Postoperative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast
Cancer
CTSU CALGB 40101
Consent
HIPAA
Fast Facts
Protocol
Treatment
Calendar
Cyclophosphamide and Doxorubicin vs. Paclitaxel as
Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph
Nodes
CTSU E5103
Consent
HIPAA
Fast
Facts
Protocol
A Double-blind Phase III Trial
of Doxorubicin and Cyclophosphamide followed by
Paclitaxel and Bevacizumab or Placebo in
Patients with Lymph Node Positive and High-risk
Lymph Node Negative Breast Cancer
NSABP B-39 Consent
HIPAA
Fast Facts
Protocol (Closed to specific patients)(QOL
closed)
Treatment Calendar
A Randomized Phase III Study of Conventional
Whole Breast Irradiation versus Partial Breast Irradiation for Women with Stage
0, I or II Breast Cancer
CTSU
Z1071 Consent
HIPAA Protocol
Treatment
Calendar
Phase
II Study Evaluating the Role of Sentinel Lymph
Node Surgery and Axillary Lymph Node Dissection
Following Preoperative Chemotherapy in Women
with Node Positive Breast Cancer (T1-4, N1-2,
M0) at Initial Diagnosis
SWOG S0800
Consent
HIPAA
Protocol
(study opening delayed)
A Randomized Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel with or
without Bevacizumab, Either Preceded by or
Followed by Q 2 Week Doxorubicin and
Cyclophosphamide plus Pegfilgrastim as
Neoadjuvant Therapy for Inflammatory and Locally
Advanced Her-2/NEU Negative Breast Cancer
Her2+
CTSU
N063D ALTTO Consent
HIPAA
Fast Facts
Protocol (Design
1 closed 3/15/09)
A Randomized, Multi-center, Open-label, Phase III
Study of Adjuvant Lapatinib, Trastuzumab, Their
Sequence and Their Combination in Patients with
HER2/ErbB2 Positive Primary Breast Cancer
Neo Adjuvant
NSABP B-40
Consent
HIPAA
Fast Facts
Protocol
Treatment Calendar Group 1A
Group 1B
Group 2A
Group 2B
Group 3A
Group 3B
A
Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and
Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR)
of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC
with or without Bevacizumab and Correlative Science Studies Attempting to
Identify Predictors of High Likelihood for pCR with Each of the Regimens
CTSU C40601
Consent
HIPPA
Protocol
Randomized Phase III Trial of Paclitaxel
Combined with Trastuzumab, Lapatinib, or Both as
Neoadjuvant Treatment of Her2-Positive Primary
Breast Cancer
Adjuvant--Hormonal
CTSU CALGB
70301 Consent
HIPAA
Schema
Protocol
Quality of Life, Employment, and Informal Care Cost Analysis in Women Receiving
Adjuvant Chemotherapy (Adjunct study for C40101)
IBCSG 24-02 Consent
HIPAA Fast Facts
Protocol
Treatment
Calendar-Arm A
Arm B
Arm C
A Phase III Trial Evaluating the Role of Ovarian
Function Suppression and the Role of Exemestane Adjuvant Therapies for Premenopausal Women
with Endocrine Responsive Breast Cancer
IBCSG 25-02 Consent
HIPAA
Protocol
Treatment
Calendar-Arm A
Arm B
A Phase III Trial Evaluating the Role of Exemestane Plus
GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast
Cancer
Ovarian Function Failure
SWOG S0230
Consent
HIPAA Fast
Facts
Protocol
Treatment
Calendar-Arm 1
Arm 2
Phase III Trial of LHRH Analog Administration During
Chemotherapy to Reduce Ovarian Failure Following Standard Adjuvant Chemotherapy in Early
Stage, Hormone-Receptor Negative Breast Cancer
Breast - Inflammatory
SWOG S0800
Consent
HIPAA
Protocol
(Study opening delayed)
A Randomized Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel with or
without Bevacizumab, Either Preceded by or
Followed by Q 2 Week Doxorubicin and
Cyclophosphamide plus Pegfilgrastim as
Neoadjuvant Therapy for Inflammatory and Locally
Advanced Her-2/NEU Negative Breast Cancer
Breast - Regional Relapse
Breast - Metastatic
SWOG S0500
Consent
HIPAA
Fast Facts
Protocol
Treatment Calendar
A Randomized Phase
II Trial to Test the Strategy of Changing Therapy vs Maintaining Therapy for
Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell
Levels at First Follow-up Assessment
SWOG S0622
Consent HIPAA
Fast Facts
Protocol
Treatment
Calendar-Arm 1
Arm 2
Phase II Studies of
Two Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant
Metastatic Breast Cancer
CTSU CALGB 40302
Consent
HIPAA Fast
Facts
Protocol
Investigator
letter Treatment
Calendar
Endocrine
Therapy with or without Inhibition of EGF and HER2 Growth Factor Receptors:
A Randomized, Double-Blinded, Placebo-controlled Phase III Trial of Fulvestrant
with or without Lapatinib for Postmenopausal Women with Hormone Receptor
Positive Advanced Breast Cancer
CTSU C40502 Consent
HIPAA
Schema
Protocol Treatment
Calendar Arm A
Arm B
Arm C
A Randomized Phase III Trial of
Weekly Paclitaxel Compared to Weekly
Nonoparticle Albumin Bound NAB-Paclitaxel or
Ixabepilone Combined with Bevacizumab as
First-line Therapy for Locally Recurrent or
Metastatic Breast Cancer
CTSU
C40503 Consent
HIPAA Fast
Facts
Protocol
Treatment
Calendar
Endocrine Therapy in
Combination with anti-VEGF Therapy: A
Randomized, Double-Blind, Placebo-Controlled
Phase III Trial of Endocrine Therapy Alone or
Endocrine Therapy Plus Bevacizumab (NSC
704865; IND 7921) For Women with Hormone
Receptor-Positive Advanced Breast Cancer
NCCTG N0733
Consent
HIPAA
Protocol Treatment
Calendar Arm A
Arm B
Phase II Trial of
Capecitabine and Lapatinib with or without
IMC-A12 in Patients with HER2 Positive Breast
Cancer Previously Treated with Trastuzumab and
an Anthracycline and/or a Taxane
GASTROINTESTINAL
Colon - Rectal
Stage II Colon
CTSU E5202
Consent
HIPAA
Protocol
A
Randomized Phase II Study Comparing 5-FU, Leucovorin and Oxaliplatin vs 5-FU,
Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer
at High Risk for Recurrence to Determine Prospectively the Prognostic Value of
Molecular Markers
Stage III Colon
Metastatic Colon
CTSU CALGB 80405
Consent
HIPAA
Fast Facts
Protocol
( QOL closed)(closure
Arm C)
Treatment
Calendar Arm A
Treatment Calendar Arm B
A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin
with Bevacizumab, or Cetuximab or with the Combination of Bevacizumab and
Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or
Rectum
NCCTG N054C Consent
HIPAA
Protocol (temporary
closure 10/15/09)
Treatment
Calendar
Phase II Study of Sorafenib/Bevacizumab as
Salvage Therapy in Patients with Metastatic
Colorectal Cancer
Small Bowel
NCCTG
N0543
Consent
HIPAA
Protocol
A Phase II Trial of
Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as
First-Line Therapy for Advanced Small Bowel Adencarcinoma
Metastatic
2nd Line
SWOG S0600
Consent
HIPAA Fast
Facts
Protocol
Treatment Calendar Arm A FOLFIRI
Arm A Irinotecan Arm
B FOLFIRI
Arm B Irinotecan
Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab or Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal
Cancer who have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX, or XELOX
Rectal
NSABP R-04
Consent
Consent tissue
HIPAA
Fast Facts
Protocol
Treatment
Calendar Group 1
Group 2
Group 3
Group 4
A Clinical Trial Comparing Preoperative Radiation Therapy and
Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of
5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum
Stomach
Esophageal
RTOG R0436
Consent
HIPAA
Protocol
A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and
Radiation for Patients With Esophageal Cancer
Who Are Treated Without Surgery
NCCTG N0747 Consent
HIPAA
Protocol
Treatment
Calendar
Randomized Phase II Trial of Sunitinib Plus
Capecitabine Versus Capecitabine Alone (with the
potential for crossover) for Elderly and/or Poor
Performance Status Patients with Adenocarcinoma
of the Esophagus or Gastroesophageal Junction
Pancreas
NCCTG N064B Consent
HIPAA
Protocol
(level 1 closed)
Randomized Phase II Trial of Panitumumab,
Erlotinib, and Gemcitabine vs Erlotinib and
Gemcitabine in Patients with Untreated,
Metastatic Pancreatic Adenocarcinoma
NCCTG N064A Consent
HIPAA
Protocol
Phase II Study of Panitumumab,
Chemotherapy and External Beam Radiation in
Patients with Locally Advanced Pancreatic Cancer
RTOG R0848 Consent
HIPAA
Protocol
A Phase III Trial
Evaluating Both Erlotinib and Chemoradiation as
Adjuvant
Treatment for Patients with Resected Head of
Pancreas Adenocarcinoma
SWOG
S0727 Consent
HIPAA
Protocol
A Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib (NSC-718781) + IMC-A12
(NSC-742460) vs. Gemcitabine + Erlotinib as
First-Line Treatment in Patients with Metastatic
Pancreatic Cancer
Liver
NCCTG N0745
Consent 1A
Consent 1B
HIPAA
Protocol
(evaluation closure 12/11/09)
Phase 1/II Randomized Study of Sorafenib and
Bevacizumab as First-Line Therapy in Patients with Locally Advanced or
Metastatic Hepatocellular Carcinoma
CTSU E1208
Consent
HIPAA
Schema
Protocol
A Phase III
Randomized Trial of Chemoembolization with or
without Sorafenib in Unresectable Hepatocellular
Carcinoma (HCC) in Patients with and without
Vascular Invasion
Gallbladder
None
Stromal
Carcinoid
SWOG
S0518
Consent
HIPAA
Protocol
(step 2 closed -
octreotide scan consent not needed)
Phase III Prospective Randomized
Comparison of Depot Octreotide Plus
Interferon Alpha Versus Depot Octreotide
Plus Bevacizumab (NSC #704865) in
Advanced, Poor Prognosis Carcinoid
Patients
Cholangiocarcinoma
SWOG S0809
Consent HIPAA
Protocol
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine
Chemotherapy Followed by Concurrent Capecitabine
and Radiotherapy in Extrahepatic
Cholangiocarcinoma (EHCC)
GENITOURINARY
Prostate-Local
CTSU CALGB 90203
Consent
HIPAA
Protocol
Randomized Phase III Study of
Neoadjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy vs
Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized
Prostate Cancer
RTOG R0622
Consent
HIPAA
Protocol
A Phase II Trial of Samarium 153 Followed by
Salvage Prostatic Fossa 3D-CRT or IMRT
Irradiation in High-Risk, Clinically
Non-Metastatic Prostate Cancer After Radical
Prostatectomy
RTOG R0815
Consent
HIPAA
Protocol
A Phase III
Prospective Randomized Trial of Dose-Escalated
Radiotherapy With or Without Short-Term Androgen
Deprivation Therapy for Patients With
Intermediate-Risk Prostate Cancer
Prostate-Recurrent
RTOG R0534
Consent
HIPAA
Protocol
A Phase III Trial Of Short Term Androgen Deprivation With Pelvic
Lymph Node Or Prostate Bed Only Radiotherapy (SPORT) In Prostate Cancer Patients
With A Rising PSA After Radical Prostatectomy
Prostate-Metastatic
SWOG S0421
Consent
HIPAA
Protocol
Treatment Calendar
Phase III Study of
Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced
Hormone Refractory Prostate Cancer
CTSU E3805
Consent
HIPPA
Protocol
CHAARTED:
Chemohormonal Therapy versus Androgen
Ablation Randomized Trial for Extensive
Disease in Prostate Cancer
CTSU CALGB 90202
Consent
HIPAA
Fast Facts
Protocol
Treatment
Calendar-Blinded
Open Label
A Randomized, Double-blind, Placebo-controlled Phase III
Study of Early vs. Standard Zoledronic Acid to Prevent Skeletal-related Events in Men with
Prostate Cancer Metastatic to Bone
CTSU MDA-3410
Consent
HIPAA
Fast Facts
Protocol
A Prospective Randomized Phase II Trial Comparing
Consolidation Therapy With or Without Strontium-89 Following Induction
Chemotherapy in Androgen-Independent Prostate Cancer
Bladder/Urothelium
RTOG R0524 Consent
HIPAA
Protocol
A
Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab with Daily
Irradiation or Paclitaxel Alone with Daily Irradiation Following Tranurethral
Surgery for Non-Cystectomy Candidates with Muscle Invasive Bladder Cancer
SWOG S0337 Consent
HIPAA
Protocol
A Phase III
Blinded Study of Immediate Post-TURBT
Instillation of Gemcitabine Versus Saline in
Patients with Newly Diagnosed or Occasionally
Recurring Grade I/II Superficial Bladder Cancer
Germ Cell Malignancies
none
Renal
CTSU
E2805
Consent
HIPAA
Fast Facts
Protocol
A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus
Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma
CTSU
E2804 Consent
HIPAA
Protocol (MRI
imaging component closed)
The BeST Trial: A
Randomized Phase II Study of VEGF, RAF kinase,
and mTOR Combination Targeted Therapy (CTT) with
Bevacizumab, Sorafenib and Temsirolimus in
Advanced Renal Cell Carcinoma
CTSU C90601
Consent
HIPAA
Protocol Treatment
Calendar
Randomized Double-Blinded Phase III Study
Comparing Gemcitabine, Cisplatin, and
Bevacizumab to Gemcitabine, Cisplatin and
Placebo in Patients with Advanced Transitional
Cell Carcinoma
GYNECOLOGIC
Ovarian
NCCTG MC0261 Consent
HIPAA
Protocol
Treatment Calendar
(closed 3/3/2010)
Phase II Trial of Flavopiridol and Cisplatin
in Advanced Epithelial Ovarian and Primary Peritoneal
Carcinomas (NCI #5876)
CTSU G0252
Consent
HIPAA
Protocol
Phase III Clinical Trial of Bevacizumab with IV
vs IP Chemotherapy in Ovarian, Fallopian tube,
and Primary Peritoneal Carcinoma
Cervical
CTSU G0240 Consent
HIPAA
Protocol
A Randomized Phase III Trial of Cisplatin plus
Paclitaxel with and without NCI-supplied
Bevacizumab vs the Non-platinum Doublet,
Topotecan plus Paclitaxel, with and without
Bevacizumab in Stage IV-B Recurrent or
Persistent Carcinoma of the Cervix
Endometrial
CTSU G0258
Consent
HIPAA
Protocol
A Randomized Phase III Trial of Cisplatin and
Tumor Volume Directed Irradiation Followed by
Carboplatin and Paclitaxel vs Carboplatin
and Paclitaxel for Optimally Debulked, Advanced
Endometrial Carcinoma
CTSU G0249
Consent
HIPAA
Protocol Treatment
Calendar
Phase III Trial of Pelvic Radiation Therapy vs
Vaginal Cuff Brachytherappy Followed by
Paclitaxel/Carboplatin in Patients with
High-Risk, Early Stage Endometrial Cancer
Uterine
CTSU
G0261
Consent
HIPAA
Protocol
A Randomized Phase III Trial of Paclitaxel Plus
Carboplatin vs Ifosfamide Plus Paclitaxel in
Chemotherapy-Naïve Patients with Newly Diagnosed
Stage I-IV Persistent or
Recurrent Carcinosarcoma (Mixed Mesodermal
Tumors) of the Uterus
HEAD & NECK
CTSU E1305
Consent
HIPAA
Protocol
A Phase III Randomized Trial of
Chemotherapy With or Without Bevacizumab in
Patients with Recurrent or Metastatic Head and
Neck Cancer
RTOG R0920
Consent
HIPAA
Protocol
A Phase III Study of Postoperative Radiation Therapy (IMRT)
+/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
LEUKEMIA
Acute Myelogenous Leukemia
SWOG 9007
Consent
HIPAA
Protocol
Cytogenetics Studies in Leukemia Patients, Ancillary
SWOG 9910
Consent
HIPAA
Protocol
Leukemia Centralized Reference Laboratories and Tissue
Repositories Consent to Perform Cellular and Molecular Studies in Leukemia Patients
SWOG S0535
Consent
HIPAA
Protocol
Phase II Study of ATRA, Arsenic
Trioxide and Gemtuzumab Ozogamicin in Patients
with Previously-untreated High-risk Acute
Promyelocytic Leukemia
SWOG S0605
Consent
HIPAA
Protocol
A Phase II Study of Lenalidomide (Revlimid)
(NSC-703813) for Previously Untreated Non-M3 Deletion 5Q Acute Myeloid Leukemia
(AML) in Patients Age 60 or Older Who Decline Remission Induction Chemotherapy
SWOG S0521
Consent
HIPAA
Protocol
A Randomized Trial of Maintenance
vs Observation for Patients with Previously Untreated Low and Intermediate risk
Acute Promyelocytic Leukemia (APL), Phase III
SWOG S0703 Consent
HIPAA
Protocol
A Phase II Trial of Azacitidine (NSC-102816)
Plus Gemtuzumab Ozogamicin as Induction and
Post-Remission Therapy in Patients of Age 60 and
Older with Previously Untreated Non-M3 Acute
Myeloid Leukemia
SWOG
S0919 Consent
HIPAA
Protocol
Phase II Study of Idarubicin and Ara-C in
Combination with Pravastatin for Relapsed Acute
Myelogenous Leukemia (AML)
Maintenance
Myelodysplastic
Syndrome
SWOG E1905
Consent
HIPAA
Protocol
A Randomized Phase II Trial of
Azacitidine with or without the Histone Deacetylase Inhibitor MS-275 for the
Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
(dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia
CTSU E2905 Consent
HIPAA
Protocol
Randomized Phase III Trial Comparing the
Frequency of Major Erythroid Response (MER) to
Treatment with Lenalidomide (Revlimid) Alone and
in Combination with Epoetin Alfa (Procrit) in
Subjects with Low- or Intermediate-1 Risk MDS
and Symptomatic Anemia
Chronic Leukemia
SWOG E1905
Consent
HIPAA
Protocol
A
Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase
Inhibitor Entinostat MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic
Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with
Multilineage Dysplasia
Lymphoblastic Leukemia
SWOG C10403 Consent
HIPAA
Protocol
(MCC treats adults only -- must be
> 18 yrs)
An Intergroup Phase II Clinical Trial for
Adolescents and Young Adults with Untreated
Acute Lymphoblastic Leukemia
SWOG S0805
Consent
HIPAA
Protocol
Phase II Study of Combination of Hyper-CVAD
and Dasatinib with or without Allogeneic Stem
Cell Transplant in Patients with Ph-Chromosome
Positive and/or Bcr-Abl Positive Acute
Lymphoblastic Leukemia (ALL)
Chronic Leukemia
CTSU
C10501 Consent
HIPAA
Fast Facts
Protocol (Pre-registration
closed 1/5/10)
A
Phase III Intergroup CLL Study of Asymptomatic
Patients with Untreated CLL Randomized to Early
Intervention vs Observation with Later Treatment
in Hi-Risk Genetic Subset with IgVh Unmutated
Disease
LUNG
SWOG 9925
Protocol (NO CONSENT)
Lung Cancer Specimen Repository Protocol,
Ancillary
Non-Small Cell
SWOG
S0424
Consent
HIPAA
Fast Facts
Protocol
(study open only
to non-smokers - fewer than 100 cigarettes in lifetime)
Molecular
Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and
Non-Smoking Women and Men
Local
RTOG R0617
Consent
HIPAA
Protocol
A
Randomized Phase III Comparison of
Standard-Dose (60 Gy) Versus High-Dose (74
Gy) Conformal Radiotherapy with Concurrent
and Consolidation Carboplatin/Paclitaxel in
Patients With Stage IIIA/IIIB Non-Small Cell
Lung Cancer
Adjuvant
CTSU E1505
Consent
HIPAA
Fast Facts
Protocol
A Phase III
Randomized Trial of Adjuvant Chemotherapy with
or without Bevacizumab for Patients with
Completely Resected Stage IB (> 4 cm) -
IIIA Non-Small Cell Lung Cancer
SWOG S0720 Consent
HIPAA Fast
Facts
Protocol
Phase II ERCC1 and RRM2-Based Adjuvant Therapy
Trial in Patients with Stage I Non-small Cell
Lung Cancer (NSCLC)
Advanced
SWOG S0635
Consent
HIPAA
Fast Facts
Protocol
Phase II
Trial of the Combination of OSI-774(Erlotinib)
and Bevacizumab in Stage IIIB
and IV Bronchoalveolar Carcinoma (BAC) and Adencarcinoma
with BAC Features (AdenoBAC)
SWOG S0636
Consent
HIPAA Fast Facts
Protocol
A
Phase II Trial of the Combination of OSI-774 (Erlotinib;
NSC-718781) and Bevacizumab (Rhumab VEGF;
NSC-704865) in Never-Smokers with Stage IIIB and
IV Primary NSCLC Adenocarcinomas
NCCTG
N0626
Consent
HIPAA
Protocol
A Phase II Randomized
Study of Pemetrexed With Sorafenib Versus
Pemetrexed Alone as Second-line Therapy in
Patients With Advanced Non-Small Cell Lung
Cancer
NCCTG N0724 Consent
HIPAA
Protocol
A Phase II Study of the Treatment of
Oligometastatic Stage IV Non-Small Cell Lung
Cancer (NSCLC) with Systemic Therapy plus
Radiotherapy to all Sites of Gross Disease
NCCTG
N0821
Consent
HIPAA
Protocol
A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in
Advanced Nonsquamous NSCLC Evaluating Efficacy
and Tolerability in Elderly patients (Age >
70 yrs) with Good Performance Status (PS <2)
SWOG S0819 Consent
HIPAA
Protocol
Treatment Calendar Arm 1a
Arm 1b
Arm 2a
Arm 2b
A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab
with or without Concurrent Cetuximab in Patients
with Advanced Non-Small Cell Lung Cancer (NSCLC)
SWOG S0709
Consent
HIPAA
Protocol
Phase II Selection Design of Pharmacodynamic
Separation of Carboplatin/Paclitaxel/Erlotinib
or Erlotinib Alone in Advanced NSCLC Patients
with Performance Status 2 Selected by Serum
Proteomics
CTSU C30607 Consent
HIPAA
Protocol
Randomized, Phase III, Double-Blind
Placebo-Controlled Trial of Sunitinib (NSC
#736511, IND #74019) as Maintenance Therapy in
Non-Progressing Patients following an Initial
Four Cycles of Platinum-Based Combination
Chemotherapy in Advanced, Stage IIIB/IV
Non-Small Cell Lung Cancer
Small
Cell
SWOG S0802 Consent
HIPAA
Protocol
Treatment Calendar
A Randomized Phase II Trial of Weekly Topotecan
with and without AVE0005 (Aflibercept;
NSC-724770) in Patients with Platinum Treated
Extensive Stage Small Cell Lung Cancer (E-SCLC)
CTSU
C30610 Consent
HIPAA
Protocol
Phase III Comparison of Thoracic Radiotherapy
Regimens in Patients with Limited Small Cell
Lung Cancer also Receiving Cisplatin and
Etoposide
NCCTG N0923
Consent
HIPAA
Protocol
A Randomized
Double-Blinded Phase II Study of NTX-010, a
Replication-Competent Picornavirus, After
Standard Platinum Containing Induction Regimens
of Cytoreductive Chemotherapy for Patients with
Extensive Stage Small Cell Lung
Lung-Other
SWOG S0722
Consent
HIPAA
Protocol
(temporary closure
09/15/09 - 1st stage accrual met)
A Phase II Trial of mTOR Inhibitor, Everolimus
(RAD001;NSC-733504) in Malignant Pleural
Mesothelioma (MPM)
LYMPHOMA
SWOG 8819
(NO CONSENT)
Protocol
Central Lymphoma Repository Tissue Procurement
SWOG 8947
Consent HIPAA
Protocol
Central Lymphoma Serum Repository
SWOG 9245 Consent
HIPAA
Protocol
Central Lymphoma Repository Tissue Procurement Protocol
for Relapse or Recurrent Disease
Hodgkin's
SWOG S0816 Consent
HIPAA
Protocol
A Phase II Trial of Response-Adapted Therapy of
Stage III-IV Hodgkins Lymphoma using Early
Interim FDG-PET Imaging
Non-Hodgkin's
SWOG S0433
Consent
HIPAA
Fast Facts
Protocol
Iodine-131-Labeled Monoclonal Anti-B1 Antibody in Combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab Therapy
for Patients Greater Than or Equal to Age 60 with Advanced Stage Diffuse Large
B-Cell NHL
CTSU CALGB 50303
Consent
HIPAA
Fast Facts
Protocol
Randomized Study of R-CHOP
versus Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated DeNovo
Diffuse Large B-Cell Lymphomas
NCCTG N0682
Consent
HIPAA
Protocol
Treatment Calendar
A Phase II Clinical
Trial of Denileukin Diftitox in Combination with Rituximab in Previously
Untreated Follicular B-Cell Non-Hodgkin's Lymphoma
SWOG S0801
Consent
HIPAA
Protocol
Treatment Calendar
A Phase II Study of Iodine-131-Labeled
Tositumomab in Combination With Cyclophosphamide,
Doxorubicin, Vincristine, Prednisone and
Rituximab Therapy for Patients With Advanced
Stage Follicular Non-Hodgkin’s Lymphoma
T-Cell
SWOG S0350
Consent
HIPAA
Fast Facts
Protocol
Phase II
Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol in Peripheral
T-cell Non-Hodgkin's Lymphoma
Mantle Cell
NCCTG N078D
Consent -1A
Consent -1B
HIPAA
Protocol
Phase I/II Trial of Tituximab,
Cladribine, and Temsirolimus (RCT) Therapy in
Newly Diagnosed Mantle Cell Lymphoma (MCL)
Melanoma
CTSU E1697 Consent
HIPAA
Protocol
Phase III Randomized Study of Four Weeks High
Dose IFN-α2b in Stage T2b No,
T3a-bN0, T4a-b
No, and T1-4, N1a,
2a (microscopic) Melanoma
SWOG S0826
Consent
HIPAA
Protocol (temporary
closure 2/9/10)
A Phase II Study of SCH 727965 in Stage IV
Melanoma
Myeloma
SWOG S0309
(No Consent)
HIPAA
Protocol
Myeloma Specimen
Repository Protocol, Ancillary
CTSU E1A05
Consent
HIPAA
Schema
Fast Facts Protocol
Randomized Phase III Trial of Consolidation
Therapy with Bortezomib (Velcade®) -
Lenalidomide (Revlimid®) - Dexamethasone (VRD)
versus Bortezomib (Velcade®) - Dexamethasone
(VD) for Patients with Multiple Myeloma Who
Have Completed a Dexamethasone-Based
Induction Regimen
CTSU E1A06
Consent
HIPAA
Protocol
An Intergroup
Phase III Randomized Controlled Trial Comparing
Melphalan, Prednisone and Thalidomide Versus
Melphalan, Prednisone and Lenalidomide in Newly
Diagnosed Myeloma Patients Who Are Not
Candidates for High-Dose Therapy
SWOG S0120
Consent HIPAA
Fast Facts
Protocol
A Prospective
Observational Biologic Study of Asymptomatic Patients With Monoclonal Gammopathy and
Plasma Proliferative Disorders
SWOG S0777
Consent HIPAA
Protocol
A Randomized
Phase III Trial of CC-5013 (Lenalidomide) and
Low Dose Dexamethasone (LLD) Versus Bortezomib
(PS-341), Lenalidomide and Low Dose
Dexamethasone (BLLD) for Induction, in Patients
with Previously Untreated Multiple Myeloma
Without an Intent for Immediate Autologous Stem
Cell Transplant
Transplant
SWOG S0115
Consent
HIPAA Fast
Facts
Protocol
Phase II Trial
Evaluating Modified High Dose Melphalan and Autologous Peripheral Blood Stem Cell
Supported Transplantation for High Risk Patients with Multiple Myeloma and/or Light Chain
Amyloidosis
Sarcoma
None
Other
NCCTG N0871
Consent
HIPAA Protocol
A Phase II Study of Carboplatin, Paclitaxel and
Everolimus in Previously Untreated Patients with
Measurable Disease with Cancer of Unknown
Primary
RTOG R0631
Consent
HIPAA
Protocol
Phase II/III Study of Image-Guided Radiosurgery/SBRT
for Localized Spine Metastasis
Return to the Top
